


How InChI helps describe and identify biopharmaceuticals

Yulia Borodina

Office of Health Informatics

Biopharmaceuticals



- Substances extracted from biological organism or synthesized on biological matrices
- Majority are proteins
- Often conjugated with small molecules, polymers or themselves in order to increase bioavailability, immunogenicity or to deliver an unspecific toxin
- Therapy of cancer, rheumatoid arthritis, migraine, asthma etc.
- Cost is very high

Biopharmaceuticals in clinical trials (Ex)

Clinical Trial

RINDOPEPIMUT



NCT Number:	NCT01480479	Recruitment:	Completed
Title:	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma	Conditions:	Glioblastoma Small Cell Glioblastoma Giant Cell Glioblastoma Gliosarcoma Glioblastoma With Oligodendrocyte Component
Sponsor:	Celldex Therapeutics Celldex Therapeutics]	Intervention:	Drug: Rindopepimut (CDX-110) with GM-CSF Drug: Temozolomide Drug: KLF
Funded Bys:	Industry	Phases:	Phase 3
Study Types:	Interventional	Age Groups:	18 Years and older (Adult, Older Adult)
Study Designs:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment	Gender:	All
Study Results:	No Results Available	Enrollment:	745
Other Ids:	CDX110-04	Acronym:	ACT IV

RINDOPEPIMUT described by USAN

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (WW-34)

RINDOPEPIMUT

PRONUNCIATION

rin'' doe pep' i mut


THERAPEUTIC CLAIM

Immunotherapy for glioblastoma multiforme and potentially other tumor types

CHEMICAL NAME

L-leucyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-.alpha.-aspartyl-L-histidyl-L-cysteine thioether with *N*-[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl) methyl]cyclohexyl]carbonyl]-keyhole limpet hemocyanin (*Megathura crenulata*) (1:?)

STRUCTURAL FORMULA



MOLECULAR WEIGHT

450-550 kDa

TRADEMARKS

Rintega™

MANUFACTURER

Celldex Therapeutics, Inc.

CODE DESIGNATION


CDX-110

CAS REGISTRY NUMBER

1108208-65-6

Hemocyanin

Keyhole limpet hemocyanin (KLH) is **a very large, copper-containing protein** molecule derived from the haemolymph of the inedible mollusc, *Megathura crenulata*. KLH is a highly immunogenic T-cell dependent antigen that is used increasingly in immunotoxicological studies, particularly in those involving animals.



We do not use InChI to define primary protein structure

Code	Amino acid	Code	Amino acid
A	alanine	I	isoleucine
R	arginine	L	leucine
N	asparagine	K	Lysine
D	aspartic acid	M	methionine
B	asparagine or aspartic acid	F	phenylalanine
C	cysteine	P	proline
E	glutamic acid	S	serine
Q	glutamine	T	threonine
Z	glutamine or glutamic acid	W	tryptophan
G	glycine	Y	tyrosine
H	histidine	V	Valine
X	(wildcard / placeholder)		


Primary protein structure is defined by amino acid single letter code

We use InChI to define modifications to the primary protein structure

- Modified amino acids
- Links
- Prosthetic groups

Example: definition of a modified amino acid


Lysine linked to Epidermal Growth Factor Receptor variant III



InChI canonical atom numbers for atoms that **substitute** N of amino group and C of carboxyl group of a natural amino acid

Example: definition of a link

CYSTEINE-GLUTATHIONE DISULFIDE




```
InChI=1S/C13H22N4O8S2/c14-6(12(22)23)1-2-9(18)17-8(11(21)16-3-10(19)20)5-27-26-4-7(15)13(24)25/h6-8H,1-5,14-15H2,(H,16,21)(H,17,18)(H,19,20)(H,22,23)(H,24,25)/t6-,7-,8-/m0/s1
```

(N,C) pairs
(14,12)
(15,13)

InChI canonical atom numbers for atoms that *substitute* N of amino group and C of carboxyl group of a natural amino acid

Example: definition of type 3 copper center



```
InChI=1S/6C6H9N3O2.2Cu/c6*7-5(6(10)11)1-4-2-8-3-9-4;;/h6*2-3,5H,1,7H2,(H2,8,9,10,11);;/q;;;;;2*+2/p-4/t6*5-;;/m000000../s1
```

(N,C) pairs

(7,6)

(18,17)

(29,28)

(40,39)


(51,50)

(62,61)

Identification

- InChI and ordered list of canonical (N,C) pairs provide that every modification is uniquely indentified
- Location of a modification in the protein is specified by positions of substituted amino acids
- For example, Type 3 copper center position in hemocyanin is (2940, 2959, 2968, 3069, 3073, 3100)
- Complete 2D chemical structure of the modified protein can be reconstructed if needed

Uncertain modifications are annotated by empirical probabilities



```
<quantity >  
  <numerator xsi:type="URG_PQ" value="30" unit="mol" >  
    <denominator value="170" unit="mol" />  
  </numerator >  
</quantity>
```

Data on (some) proteins with UNIs are published

- Substance structures in XML format

<https://dailymed.nlm.nih.gov/dailymed/spl-resources-all-indexing-files.cfm>

- Substance names in text format

<https://fdasis.nlm.nih.gov/srs/>

- Other product-related information in XML format

<https://dailymed.nlm.nih.gov/dailymed/>

- SPL Substance Implementation Guide is #14 in

<https://www.fda.gov/media/84201/download>

Protein descriptions provided by PubChem are misleading

PubChem

About


Blog

Submit

Contact

COMPOUND SUMMARY

Aprutumab ixadotin

PubChem CID:	71471223
Structure:	 2D Find Similar Structures
Molecular Formula:	$C_{57}H_{95}N_9O_{11}$
Chemical Names:	UNII-OP0KZ535MV OP0KZ535MV Ixadotin Aprutumab ixadotin DDD2AB5TWK

**This is not
Aprutumab ixadotin**

Protein descriptions provided by PubChem are misleading




[About](#) [Blog](#) [Submit](#) [Contact](#)

COMPOUND SUMMARY

Hemoglobin glutamer-256 (Human)

PubChem CID: 72941846

Structure:



[Find Similar Structures](#)


Molecular Formula: $C_{13}H_{18}NO_8P$

Chemical Names:

Polyheme
Hemoglobin glutamer-256
UNII-353O60Z7Q1
Hemoglobin glutamer-256 (human)
353O60Z7Q1

kDa

Hemoglobin Glutamer



* Clinical Investigator's Brochure, Version: IBHEM-003.20 Sept05

Hemopure
Intravenous Solution